Martin Douglas Phillips MD
Clotting Disorder, Hemophilia & Bleeding Disorder
Biotech executive
Join to View Full Profile
PO Box 802Bryn Mawr, PA 19010
Dr. Phillips is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Martin Phillips is a hematologist based in Bryn Mawr, PA, with a focus on clotting disorders, hemophilia, and bleeding disorders. He has almost 30 years of pharmaceutical and biotech leadership experience, and is currently the CEO of Opsidio, a clinical stage biotech developing an antiinflammatory monoclonal antibody. He graduated from Wayne State University School of Medicine in 1982. Dr. Phillips has contributed to medical literature with several publications, including works published in the American Journal of Physiology, Mucosal Immunology, and Gynecologic Oncology, among others. His research has been cited multiple times, reflecting his engagement with topics such as stem cell factor and monoclonal antibodies in cancer therapy.
Education & Training
Wayne State University School of MedicineClass of 1982
Certifications & Licensure
PA State Medical License 1998 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 9 citationsInhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.Andrew J. Rasky, David M. Habiel, Susan B. Morris, Matthew Schaller, Bethany B. Moore
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2020-01-01 - 23 citationsGroup 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease.Wendy Fonseca, Andrew J. Rasky, Catherine Ptaschinski, Susan H. Morris, Shannon K.K. Best
Mucosal Immunology. 2019-01-07 - 110 citationsFarletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Deborah K. Armstrong, Allen J. White, Susan C. Weil, M. Phillips, Robert L. Coleman
Gynecologic Oncology. 2013-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
